Independent Research Notice: Independent StonkBuilder Community research publication. Not affiliated with, operated by, or endorsed by Neuralink Corp. or PreStocks. Neuralink devices are investigational and have not received FDA marketing authorization. Nothing here is medical, legal, or financial advice. PreStocks tokens are not Neuralink shares, confer no shareholder rights, and are unavailable to U.S. persons and residents of prohibited jurisdictions.
A Closer Look · 16 slides
Neuralink: A Closer Look
How the implant works, what participants have demonstrated, and what remains uncertain. This presentation is by StonkBuilder Community, with sources checked on 30 Oct 2026. Read all 16 slides below, or download a copy.
Slide 01 · Independent Research BriefingIndependent StonkBuilder Research · Cutoff 30 Oct 202601 / 16
Neuralink: A Closer Look
How the implant works, what people have done with it in trials, and the questions that still need answers. Includes a guide to the separate PreStocks token.
Research cutoff30 Oct 2026
Official videos analyzed44 uploads (100%)
Registered human trialsPRIME, CONVOY, VOICE
AuthorshipStonkBuilder Community
Independent authorship. Prepared by StonkBuilder Community; not operated or endorsed by Neuralink Corp. or PreStocks.
Primary-source discipline. Every technical metric, trial status, and financial figure carries a verified source and consultation date.
Strict separation of claims. Company demonstrations, clinical study endpoints, peer-reviewed literature, and future speculation are labeled distinctly.
Slide 01 takeaway: Start here to inspect the hardware, watch the primary video evidence, and understand the boundary between private Neuralink equity and PreStocks exposure.
Cervical spinal cord injury, brainstem stroke, and amyotrophic lateral sclerosis (ALS) disrupt the motor output cables while cortical computation remains active.
Target conditionsQuadriplegia, SCI, ALS, aphasia
Core bottleneckLow-bandwidth assistive inputs
Cortical signal sourceMotor & speech motor cortex
Therapeutic mechanismBypass, not biological cure
Loss of movement and speech. People with severe paralysis or bulbar-onset ALS often rely on eye-trackers or sip-and-puff switches that fatigue quickly and fail outdoors.
Intact cortical intent. Neurons in the primary motor cortex and ventral premotor/speech areas still fire in coordinated patterns when a person intends to move a hand or speak a word.
The engineering thesis. If a high-channel wireless implant can read those spikes reliably for years without percutaneous wires, software can route intention directly to computers, voice synthesizers, and mobility devices.
Slide 02 takeaway: An intracortical BCI creates a digital bypass around injured nerves; it does not biologically regenerate the spinal cord or halt ALS neurodegeneration.
Prior intracortical arrays proved humans could control cursors with thought, but rigid silicon needles and skull-mounted pedestals limited scale and home use.
Electrode channels1,024 per N1 implant
Cortical threads64 flexible polymer threads
Form factorFlush with skull, wireless
Charging & dataInductive power + Bluetooth
No percutaneous connector. The N1 implant sits beneath the scalp in a cranial recess, eliminating the skin-penetrating pedestal used by legacy laboratory research systems.
Flexible polymer threads. Instead of a rigid bed of silicon spikes that shifts against brain micromotion, 64 ultra-thin threads flex with cortical pulsatility.
Robotic insertion at scale. Because flexible threads cannot be pushed into tissue by hand, the custom R1 surgical robot inserts them needle-by-needle under micron-scale optical guidance.
Slide 03 takeaway: Neuralink treats the implant, insertion robot, and decoding software as one vertically integrated medical device platform.
From extracellular action potentials in motor cortex to calibrated cursor velocity, click intent, and synthesized speech tokens.
Signal typeAction potentials (spikes) + LFP
Peak cursor rate11.32 bits per second (BPS)
Pretraining corpus>50,000 hrs neural data
Latency targetReal-time closed loop (<50 ms)
1. On-chip amplification & spike detection. Custom ASICs inside the N1 enclosure digitize microvolt voltage fluctuations across 1,024 electrodes and extract spike events.
2. Wireless telemetry. Packetized neural features stream wirelessly to the Neuralink App on the user's computer, tablet, or phone.
3. Adaptive neural decoding. Machine-learning models map firing patterns to 2D velocity vectors, discrete clicks, or phoneme probabilities, using self-supervised pretraining to reduce daily recalibration.
Slide 04 takeaway: Closing the visual or auditory feedback loop lets participants adapt alongside the model, turning raw cortical firing into fluent control.
Jun 2026 milestoneFirst clinical transdural surgery
N1 hermetically sealed package. Combines low-power recording electronics, wireless radio, and an inductively rechargeable battery in a coin-sized enclosure.
R1 optical guidance. Multiple cameras and imaging systems map cortical blood vessels so the needle places threads within microns of target neurons while avoiding vasculature.
Deleting the durotomy (30 Jun 2026). At UHN Toronto Western Hospital, Neuralink inserted threads straight through the tough dura mater (>10× thicker than a thread) without cutting it open.
Slide 05 takeaway: Keeping the dura intact reduces surgical complexity and cerebrospinal fluid exposure, a critical step toward safer, repeatable procedures.
Surgical Engineering Milestone · 30 June 2026 (Toronto Western Hospital)Why inserting threads through the intact dura mater (“deleting the durotomy”) matters
Every milestone anchored to dated regulatory filings, clinical registries, and official video records.
2019–2022Preclinical prototypes & R1 robot
May 2023FDA IDE clearance for PRIME
Jan 2024First human N1 implant
Jan–Oct 202621 participants, VOICE & transdural
Preclinical validation (2019–2022). Evolved from wired USB-C research boards (2019) to wireless porcine recording (2020), macaque MindPong (2021), and full R1 robot verification (2022).
First-in-human launch (2023–2024). Opened PRIME (NCT06429735) in late 2023, completed the first human implant in January 2024, and resolved early thread-retraction challenges via decoding and deeper insertion.
Multi-study clinical expansion (2025–2026). Added CONVOY (robotic arm), VOICE (NCT07224256, speech restoration), international sites (Canada, UK), and reached 21 participants by 28 January 2026.
Slide 06 takeaway: Track progress by completed clinical milestones and peer-reviewed data rather than aspirational calendar targets.
Primary-Source Chronology · 2019 to Oct 2026Seven years from benchtop polymer threads to multi-center human clinical studies
Slide 07 · PRIME Study & TelepathyDemonstrated in Human Feasibility Trials (PRIME)07 / 16
Using a computer at home
How PRIME participants use Telepathy unsupervised at home for CAD, gaming, digital painting, writing, and communication.
Registered studyPRIME · NCT06429735
Enrolled count21 participants (as of 28 Jan 2026)
Peak cursor BPS11.32 bits per second
Daily usageMulti-hour independent home use
High-throughput cursor and click control. Participants map imagined or attempted movements to smooth cursor trajectories and multi-button clicks across macOS, Windows, and iOS.
Creative and technical workflows. Official videos document Audrey creating digital artwork (5hYg3rUfLiQ, R03-DWvWmAY), participants signing their physical handwriting (MYKEycYqRpk), CAD modeling, and strategy gaming.
First-participant transparency. After partial thread retraction reduced raw channels in the first participant, software switched to population-level local field potentials (LFPs) and restored higher BPS than baseline.
Slide 07 takeaway: Real-world utility depends on sustained home reliability and low calibration overhead across months, not just peak single-session speed.
Telepathy Pipeline · PRIME Study (NCT06429735)How motor-cortex firing becomes smooth 2D cursor trajectory and multi-click control
Slide 08 · VOICE Clinical TrialActive Early Feasibility Study · NCT0722425608 / 16
The VOICE trial: turning intended speech into audio
Decoding speech motor cortex activity in real time for participants with ALS and severe dysarthria.
Registered studyVOICE · NCT07224256
First-week speed75 WPM (company-reported)
Word error rate5.8% WER (single participant)
Voice outputPersonalized natural voice clone
Direct speech-motor decoding. Instead of spelling letter-by-letter with a 2D cursor, VOICE records directly from cortical areas governing vocal-tract musculature (nl_speech, ct_voice).
Speaking in one's own voice. In March–October 2026 updates (u8mmn9lOIyw, _j806JHhCRo, emi5O7LeiyU), participants Kenneth and Terry trained decoders by miming and then thinking words, heard aloud in their pre-ALS voice.
72-hour in-home engineering sprint (29 Oct 2026). Engineers worked directly in a participant's home (emi5O7LeiyU) to prototype low-latency conversation tools, silence false triggers, and streamline everyday dialogue.
Slide 08 takeaway: Speech neuroprostheses are advancing rapidly, supported by both Neuralink's VOICE trial and 2025 Nature / Nature Neuroscience peer-reviewed studies.
Translating high-dimensional cortical intent into multi-joint robotic manipulation and powered mobility.
Robotic arm studyCONVOY feasibility trial
Wheelchair demoJul 2026 camera-guided control
Degrees of freedomContinuous proportional velocity
Current stageSupervised clinical feasibility
CONVOY Assistive Robotic Arm (ARA). Launched in November 2024 so PRIME participants could map neural signals to a multi-axis robotic arm for feeding, grasping, and physical tasks (nl_convoy, yt_iINSOB63WnQ).
Telepathic wheelchair control (Jul 2026). Videos 78m32VSOMBk and V06QXVSWxDs show a participant driving a powered wheelchair via a live camera feed where cursor displacement controls direction and speed.
Safety gates for physical actuators. Moving heavy physical hardware requires collision avoidance, dead-man stops, latency bounds, and sensory feedback before unsupervised outdoor use.
Slide 09 takeaway: Controlling physical robotics introduces mechanical safety requirements far stricter than moving a screen cursor.
Clinical & Investigational Portfolio · Checked 30 Oct 2026Separating PRIME, CONVOY, VOICE, and Blindsight by registry status and neural direction
Slide 10 · Cortical Stimulation & VisionPreclinical / Breakthrough Designation · Not Yet in Humans10 / 16
Blindsight: research into artificial vision
Why restoring sight by stimulating primary visual cortex (V1) is a fundamentally different engineering problem from reading motor cortex.
FDA statusBreakthrough Device (Sep 2024)
Target regionPrimary visual cortex (V1)
MechanismElectrical microstimulation (write)
Human clinical dataNone published as of Oct 2026
Bypassing eye and optic nerve. Blindsight aims to capture video from external glasses and stimulate V1 electrodes so people who lost both eyes and optic nerves perceive structured phosphenes (nl_blindsight).
What FDA Breakthrough Designation means. Granted in September 2024, it provides prioritized FDA review interaction for serious unmet needs (fda_breakthrough)—it is not clinical trial results or commercial approval.
Preclinical macaque evidence. In the Summer 2025 update (FASMejN_5gs), engineers reported monkeys making eye movements toward virtual targets evoked by Blindsight stimulation.
Slide 10 takeaway: Keep Blindsight's stimulation safety, tissue charge limits, and regulatory state strictly separate from Telepathy's motor-recording results.
How Neuralink compares with other brain interfaces
Every neural interface balances spatial resolution and information throughput against surgical invasiveness.
Intracortical (N1)Single-neuron spikes · cranial surgery
Rigid Utah arrayProven 20-yr history · percutaneous
Subdural ECoGCortical surface · high-gamma LFP
Endovascular / EEGBlood-vessel or scalp · lower bandwidth
Intracortical flexible threads (Neuralink N1). Places 1,024 electrodes inside the cortex for single-neuron spike resolution in a wireless package, requiring robotic craniotomy (nl_tech).
Cortical surface (ECoG) & rigid microarrays. ECoG grids sit on the brain surface without penetrating parenchyma (strong speech results in academic trials); Blackrock Utah arrays penetrate cortex with rigid needles.
Endovascular (Synchron) & non-invasive (EEG). Endovascular stents reach motor cortex via the jugular vein without open craniotomy but record broader vessel-wall signals; scalp EEG avoids surgery entirely at low spatial resolution.
Slide 11 takeaway: No single BCI modality dominates every patient profile: clinical choice depends on whether a patient needs high-DOF cursor/voice throughput or a minimally invasive switch.
Multi-year hardware survivability. Implants must resist corrosive cerebrospinal fluid, mechanical strain, battery degradation, and gliosis over 5–10+ years (fda_bci, yt_YreDYmXTYi4).
Surgical reproducibility. Transdural insertion (F8p2MamNBgE) and automated R1 workflows (KO53gwuqZUQ) must prove safe across diverse hospital neurosurgery teams, not just flagship centers.
Pivotal trials & reimbursement. FDA Class III implanted neurological devices require rigorous pivotal trial endpoints, manufacturing quality systems, long-term follow-up, and payer coverage (fda_neuro).
Slide 12 takeaway: Early feasibility videos prove what is possible; multi-year clinical data and regulatory review determine when a device becomes standard medical care.
Surgical Engineering Milestone · 30 June 2026 (Toronto Western Hospital)Why inserting threads through the intact dura mater (“deleting the durotomy”) matters
Tier 4 (Speculative)Consumer enhancement & AI merge
Tier 1 — Demonstrated in trials. Unsupervised home computer control (PRIME), early natural-voice speech synthesis (VOICE), and supervised assistive robotic arm/wheelchair tests (CONVOY).
Tier 3 & Tier 4 — Separate programs vs. speculation. Blindsight requires its own human clinical trials; consumer memory or 'mind reading' claims remain outside current neurobiology.
Slide 13 takeaway: Evaluate every future claim by asking: Is the neural code known, does the hardware reach that brain region safely, and has a human trial tested it?
Thread retraction & chronic signal longevity. First-participant thread retraction showed that brain motion can pull electrodes out of cortex; long-term 2–5 year channel retention curves are needed.
Neural privacy & decoder false positives. Speech decoders must only vocalize intended speech (emi5O7LeiyU) and never leak private inner monologue without explicit user gating.
Trial dependency & corporate continuity. Implanted participants rely on ongoing software support, cloud/app compatibility, and surgical follow-up.
Slide 14 takeaway: Look for peer-reviewed clinical publications reporting full cohort denominators, adverse-event rates, and multi-year signal retention.
The NEURALINK PreStocks token: what you hold and what you risk
How eligible non-U.S. readers can inspect or access Neuralink-related economic exposure on Solana—and how it differs from owning Neuralink Corp. stock.
Product & symbolNeuralink PreStocks · NEURALINK
Solana mintPrekqL…bw9S (Token-2022)
Shareholder rightsNone (0% equity, vote or dividend)
EligibilityNon-U.S. only; 36 jurisdictions barred
Not a Neuralink share. Neuralink Corp. is private (last announced round: $650M Series E at reported $9B pre-money in Jun 2025). NEURALINK is issued by PreStocks and confers no shareholder or voting rights (prestocks_faq).
Verified contract address. Only PrekqLJvJ3qVdXmBGDiexvwUTF4rLFDa6HWS4HJbw9S on Solana matches PreStocks' official registry (prestocks_api, solscan_nl).
Fees, issuer controls & liquidity risk. The Token-2022 mint carries a built-in transfer fee (1% on 30 Oct 2026; 3% on 30 Sep 2026) and issuer authority (WV9PJN…ti5Wc) for freeze, pause, and permanent delegate.
Slide 15 takeaway: Always verify eligibility at prestocks.com/neuralink, check the full 44-character mint on Solscan, and distinguish provider marks from executable quotes.
Economic Exposure Structure · Verified 30 Oct 2026Private Neuralink Corp. shares vs. PreStocks' NEURALINK Token-2022 instrument
Slide 16 takeaway: Questions or corrections? Message @stonkbuilder8 on X. StonkBuilder support will never ask for your recovery phrase.
Anti-Spoofing Checklist · Solana Token-2022Verify the exact 44-character mint and Token-2022 extensions before any interaction
1 · Ticker is not identity
Anyone can deploy a Solana token named NEURALINK. Match the complete 44-character address character-for-character: PrekqLJvJ3qVdXmBGDiexvwUTF4rLFDa6HWS4HJbw9S.
2 · Confirm Token-2022 program & authority
On Solscan, confirm the token uses the Token-2022 Program, 9 decimals, and PreStocks authority WV9PJN7XTmTL…q6Fti5Wc.
3 · Check active transfer-fee bps & pool depth
Read the current transferFeeConfig on-chain (100 bps / 1% on 30 Oct 2026; 300 bps / 3% on 30 Sep 2026) and compare executable DEX impact against the provider mark.
